---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009681"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:46:11.191855+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncocyte Q1 revenue $2.14M, gross margin 62%; transplant trial gets IRB approval

## Summary
- Q1 2025 pharma services revenue $2.14M with 62% gross margin, up from 40% in Q4 2024.
- Net loss $6.7M ($0.26 per share); non-GAAP loss from operations $5.0M.
- Clinical trial design completed, central IRB approved; three top-10 US transplant centers expected to participate.
- Ten leading transplant centers now using GraftAssure RUO kits; company plans to rename in Q2.
- Cash balance $32.7M at quarter-end, including $28.7M net from February offering; Q1 operating cash use $5.9M.

## SEC filing metadata
- accession: 0001641172-25-009681
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000164117225009681/0001641172-25-009681-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000164117225009681/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009681
- JSON: https://secwatch.observer/filing/0001641172-25-009681.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009681.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.